Diversity and Emerging Roles of Enhancer RNA in Regulation of Gene Expression and Cell Fate

Preston R. Arnold¹,²*, Andrew D. Wells³ and Xian C. Li²

¹ Texas A&M Health Science Center, College of Medicine, Bryan, TX, United States, ² Immunobiology and Transplant Sciences, Department of Surgery, Houston Methodist Hospital, Houston, TX, United States, ³ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

Enhancers are cis-regulatory elements in the genome that cooperate with promoters to control target gene transcription. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes. Thus, for a long time, the question as to how enhancers act in a temporal and spatial manner attracted considerable attention. The recent discovery that enhancers are also abundantly transcribed raises interesting questions about the exact roles of enhancer RNA (eRNA) in gene regulation. In this review, we highlight the process of enhancer transcription and the diverse features of eRNA. We review eRNA functions, which include enhancer-promoter looping, chromatin modifying, and transcription regulating. As eRNA are transcribed from active enhancers, they exhibit tissue and lineage specificity, and serve as markers of cell state and function. Finally, we discuss the unique relationship between eRNA and super enhancers in phase separation wherein eRNA may contribute significantly to cell fate decisions.

Keywords: eRNA, enhancer, super enhancer, phase separation, gene regulation, non-coding RNA

INTRODUCTION

Enhancers are short regulatory elements of accessible DNA that help establish the transcriptional program of cells by increasing transcription of target genes. They are bound by transcription factors, co-regulators, and RNA polymerase II (RNAP II). Enhancers are flanked by histones with permissive chromatin markers, including H3K4 methylation (H3K4me) and H3K27 acetylation (H3K27ac). While promoters direct gene transcription in a position- and orientation-dependent manner, enhancers traditionally function independendy of their position and orientation with respect to their target gene, as they can loop over long genomic ranges to engage distant promoters (Kim et al., 2015). Despite the fundamental role of enhancers in cellular biology, we are still learning about the mechanisms by which they promote gene transcription, and consequently, cell fate decisions.

A surprising discovery regarding enhancers was made in 2010, when it was shown that enhancer regions are actively transcribed (De Santa et al., 2010; Kim et al., 2010). The product of this transcription, termed “enhancer RNA” or “eRNA,” has subsequently been the source of great debate and speculation. While pervasively observed, the role of most eRNAs has remained enigmatic. This has lead many to suggest that enhancer transcription is the noisy byproduct of transcription...
machinery. However, a growing number of studies suggests diverse roles for eRNA in regulating many aspects of cell functions. Notwithstanding, it remains unclear whether eRNA which functions are generalizable. It is also unclear how eRNA structure is related to its functional relationships in complex gene regulation machinery.

While enhancers are critical to all cell types, eRNA abundance varies dramatically across tissues. The FANTOM5 project identified immune cells, neural tissues, and hepatocytes among those with the highest abundance of cell-specific enhancers, a higher ratio of enhancers/gene, and high enhancer transcription (Andersson et al., 2014a). Indeed, studies in neurons, macrophages, and other immune cells are prominent among those contributing to our understanding of enhancers and eRNA. In contrast, smooth muscle, fibroblasts, and epithelial cells tend to utilize enhancers with less cell-specificity and have a lower enhancer/gene ratio (Andersson et al., 2014a). This diversity of enhancer utilization likely reflects the unique roles and needs of each cell type to dynamically respond to its environment.

In this review, we outline current understanding of eRNA production, structure, and classification, and discuss recent findings concerning eRNAs in gene regulation. Finally, we discuss super-enhancers, their relationship with eRNA, and the potential roles of eRNA in super-enhancer formation and structure, as well as their roles in phase separation and cell fate decisions.

**CELLULAR PRODUCTION OF eRNA**

The genome-wide transcription of enhancer regions by RNAP II was first reported by Kim et al. (2010) in neurons and by De Santa et al. (2010) in macrophages. This transcription is accompanied by the presence of both general transcription factors and lineage-specific transcription factors at the enhancer loci (Koch et al., 2011; Hah et al., 2013; Kaikkonen et al., 2013; Pulakanti et al., 2013; Cauchy et al., 2016). Extracellular stimuli drive signaling pathways which remodel chromatin and alter eRNA and mRNA expression (Kaikkonen et al., 2013; Heward et al., 2015). eRNA transcription occurs very early in the gene transcription process, preceding mRNA expression from adjacent cis loci (Schaukowitch et al., 2014; Arner et al., 2015; Kim et al., 2015; Baillie et al., 2017; Shií et al., 2017; Tyssowski et al., 2018). Indeed, the ubiquitous and early production of eRNAs makes them an excellent marker for segregating active versus quiescent enhancers, which is discussed in greater detail below (Andersson et al., 2014a; Tyssowski et al., 2018).

The process of eRNA production proceeds through the following steps: (1) recruitment of transcription factors and coactivators necessary for enhancer formation and gene activation, (2) histone modifications at the active enhancer loci, and (3) eRNA transcription, elongation, and processing (Kaikkonen et al., 2013; Figure 1).

Stimulus-dependent and/or cell type-specific transcription factor and cofactor binding at specific sites in the genome are critical first steps to the formation and activation of enhancers (Kaikkonen et al., 2013; Arner et al., 2015). In macrophages, multiple signaling pathways and transcription factors induce a pro-inflammatory gene program and eRNA transcription in response to LPS (Heward et al., 2015). In some cases transcription factors bind to constitutively accessible DNA at existing enhancer regions, while in other cases de novo nucleosome remodeling precedes enhancer activation and eRNA transcription (Kaikkonen et al., 2013; Ortega et al., 2018). Specific histones, such as H2A.Z, may be necessary for the loosening of DNA from nucleosomes at enhancer regions. Such loosening allows transcription factors to bind and enact enhancer functions (Brunelle et al., 2015). Once bound, transcription factors recruit coactivators and other complexes of DNA binding proteins (such as the MegaTrans complex in breast cancer cells) that are necessary for enhancer activation, eRNA transcription, and gene trans-activation (Liu et al., 2014). Thus, transcription factor binding with subsequent recruitment of additional cofactors and complexes provides the initial framework for enhancer activation and eRNA transcription.

Transcription at enhancer regions is dependent on epigenetic modification of histones and DNA. These processes are mediated by histone modifying and DNA demethylating components of coactivator complexes (Stadler et al., 2011; García-González et al., 2016), with H3K27ac and H3K4me1/2 being the most pervasively associated with actively transcribed enhancers (Djebali et al., 2012). H4K8 and H3K27 acetylation by the p300 and CBP histone acetyltransferases occurs following transcription factor binding and concordantly with eRNA production (Kaikkonen et al., 2013). Inhibition of their acetyltransferase activity results in concomitant loss of H3K27ac, RNAP II occupancy, eRNA transcription, and enhancer function (Jiao et al., 2018; Raisner et al., 2018). The H3K27me2/3 demethylase Kdm6a/b was also shown to act as a coactivator of eRNA transcription (Li et al., 2017; Kyzar et al., 2019). Conversely, recruitment of repressive Polycomb H3K27 methyltransferases or histone deacetylases (HDAC) have been shown to decrease eRNA expression (Cao et al., 2002; Kaikkonen et al., 2013; Lam et al., 2013). The dependence of eRNA transcription on histone acetylation is due in part to the recruitment of Bromodomain-Containing Protein 4 (BRD4) to enhancer regions by di-acetylated nucleosomes. BRD4 facilitates RNAP II recruitment and elongation through hyperacetylated enhancer regions (Kanno et al., 2014). BET inhibitors, which interfere with the ability of BRD4 bromodomains to interact with acetylated histones, also inhibit eRNA transcription (Kanno et al., 2014; Rahnamoun et al., 2018). Thus, histone acetylation not only marks enhancer sites but is crucial for eRNA production and enhancer function, likely through BRD4-dependent mechanisms.

In addition to histone modifications, enhancers exhibit decreased DNA methylation (Stadler et al., 2011), and actively transcribed enhancers show decreased DNA methylation compared to non-transcribed enhancers (Pulakanti et al., 2013). In mouse embryonic stem cells, these hypomethylated, actively transcribed regions were occupied by TET family DNA hydroxylases, which can actively demethylate CpG dinucleotides (Stadler et al., 2011). In a liver cancer model, hypomethylated DNA was shown to be necessary for eRNA production as targeted DNA demethylation through a Cas9-TET1 fusion increased eRNA production (Xiong et al., 2019). In another
Arnold et al. eRNA Regulates Cell Fate Decisions

FIGURE 1 | eRNA transcription, elongation, and termination. (A) Activated transcription factors bind the enhancer locus and promote nucleosome remodeling. They recruit other transcription factors, cofactors, complexes such as Mediator, and histone modifiers such as P300/CBP. (B) P300/CBP acetylates H3K27, which further opens the enhancer locus and recruits additional proteins such as BRD4 and RNAPII. (C) The CTD of RNAPII is phosphorylated at Ser5. WDR82 binds and recruits MLL methyltransferases, which act as cofactors to initiate RNA transcription. 5' capping machinery is also recruited to Ser5P and caps the nascent RNA strand. (D) BRD4 and other cofactors facilitate RNAPII transition to elongation, which results in an increase in Ser2P marks on the CTD of RNAPII and methylation of H3K4. However, PASs shortly downstream of the TSS are recognized by WDR82. This leads to recruitment of polyadenylation machinery and Integrator to terminate RNA transcription. Additionally, the RNA exosome is recruited and binds the 5' cap, leading to rapid degradation of RNA. KDM2A recruits NEDD4 to RNAPII leading to its ubiquitination and dismissal.

study, the knockdown of TET1 and TET2 decreased eRNA production at some enhancers but not others (Pulakanti et al., 2013). Therefore, while DNA demethylation appears to be important for enhancer activation and transcription, the mechanism and role of DNA demethylation and TET enzymes in eRNA production remain uncertain.

The details and mechanisms of enhancer transcription, initiation, and elongation are similar to those found at promoter sites, and the similarities between eRNA, IncRNA, PROMPT, and mRNA transcription have been thoroughly reviewed (Li et al., 2016). Critical to eRNA transcription is the phosphorylation of the C-terminal domain (CTD) of RNAPII and an abundance of poly(A) signals (PAS) immediately downstream of the transcription start site (TSS). Phosphorylation of Tyr1 residues on the CTD is associated with enhancer transcription and RNAPII stability (Descostes et al., 2014). RNAPII at enhancers has high levels of Ser5P relative to Ser2P on its CTD, indicative that it is not undergoing prolonged elongation (Koch et al., 2011; Pulakanti et al., 2013). This is likely due to the abundance of PAS which are bi-directionally found immediately downstream of enhancer TSSs (Ntini et al., 2013; Andersson et al., 2014a,b; Austenaa et al., 2015). Polyadenylation of eRNA has been shown to promote exosome recruitment, RNAPII instability, and transcription termination (Henriques et al., 2018). The adaptor protein WDR82 is important for RNAPII recognition of PAS and is necessary for transcription termination and cleavage of short RNA molecules such as PROMPTs and eRNA (Austenaa et al., 2015). Similarly, the INTS9 and INTS11 subunits of the Integrator complex contain nuclease activity necessary for cleaving snRNAs and eRNAs from RNAPII (Lai et al., 2015; Skaar et al., 2015). Loss of WDR82 or Integrator prevented cleavage of eRNA transcripts from RNAPII, leading to unusually long eRNAs and accumulation of unprocessed primary eRNA transcripts. These studies demonstrate the importance of WDR82 and Integrator to transcriptional termination at enhancers and eRNA maturation (Austenaa et al., 2015; Lai et al., 2015).

Interestingly, Integrator and WDR82 are involved in both the preparatory and terminating steps of eRNA transcription. WDR82 also plays a role in recruiting MLL methyltransferases to enhancers (Austenaa et al., 2015). These methyltransferases methylate H3K4 to H3K4me1/2 during transcription and have also been shown to act as coactivators of eRNA transcription independently of their methyltransferase activity (Dorighi et al., 2017). In macrophages, the INTS13 subunit of Integrator interacts with the EGR1/2 transcription factors and the NAB2 cofactor to bind and activate poised enhancers (Barbieri et al., 2018). This biological coupling of eRNA initiation and termination suggests careful regulation of eRNA and implicates eRNA molecules as more than simple accidental transcriptional noise.

STRUCTURE AND HETEROGENEITY OF eRNA

Enhancer RNAs represent a diverse class of molecules in terms of their structure and transcription patterns. Originally described as non-polyadenylated, bidirectionally transcribed RNA transcripts of less than 2 kb that originate from active enhancers marked by H3K4me1 (Kim et al., 2010), it was subsequently shown that some eRNAs can be polyadenylated or unidirectionally transcribed. Polyadenylated eRNAs are frequently longer (up to 4 kb), unidirectionally transcribed, and transcribed from higher-activity enhancers than are
their bidirectional, non-polyadenylated counterparts (Koch et al., 2011). The genome-wide FANTOM5 enhancer atlas largely corroborated these distinctions, showing that the majority of eRNAs are short (median of 346 nucleotides), bidirectionally transcribed, unspliced, and non-polyadenylated (Andersson et al., 2014a). However, incredible heterogeneity has been noted among all structural aspects of eRNAs. Nearly all combinations of transcriptional directionality, length, splicing, and polyadenylation have been reported (Hsieh et al., 2014; Alvarez-Dominguez et al., 2017; Jiao et al., 2018). Many enhancers produce eRNA bidirectionally but with the predominant production coming from either the negative or positive strand (Pulakanti et al., 2013; Andersson et al., 2014b; Schaukowitch et al., 2014). In at least one report, it was shown that the dominantly transcribed eRNA also provided the majority of biological function ascribed to eRNA from that enhancer (Hsieh et al., 2014). Additionally, single-cell CAGE sequencing revealed that while on a bulk level enhancers can be described as bi-directionally transcribed, on a single-cell level enhancers are almost exclusively unidirectionally transcribed from either strand (Kouno et al., 2019). This observation complicates the absolute classification into bidirectionally or unidirectionally transcribed. Thus, the directionality of enhancer transcription is more complex than “unidirectional” or “bidirectional” and truly exists along a gradient of strand transcriptional preference.

The polyadenylation of eRNA is not universal (Djebali et al., 2012), perhaps due to active 3′ degradation of eRNAs (Pefanis et al., 2015). The nuclear RNA exosome is known to degrade the 3′ end of eRNAs (Andersson et al., 2014a,b; Pefanis et al., 2015; Imamura et al., 2018). Because the distance between TSS and PAS is inversely correlated with RNA exosome sensitivity, it has been speculated that close proximity between the TSS and the PAS prevents the complete assembly of polyadenylation machinery on the C-terminal-domain of RNAP II. This leads to suboptimal polyadenylation, RNA exosome intervention, and rapid degradation (Ntini et al., 2013). Such a model would explain why longer eRNAs tend to be polyadenylated, and is supported by studies that have examined specific eRNA length, polyadenylation, and degradation (Schaukowitch et al., 2014; Tsai et al., 2018). Additional studies have found that the same eRNAs can be detected through RT-PCR using oligo-dT or random hexamer primers, with the oligo-dT primers generally providing weaker signal (Hah et al., 2013; Pulakanti et al., 2013). This matches eRNA transcription termination studies wherein shorter eRNAs are sub-optimally polyadenylated and subjected to rapid degradation.

In addition to primary structure heterogeneity, eRNAs demonstrate diverse secondary structures that model those seen in tRNAs, miRNAs, snRNAs, and IncRNAs (Cheng et al., 2015; Ren et al., 2017). Some eRNA molecules contain different domains with unique functions (Cajigas et al., 2018; Gichewicz et al., 2018; Tsai et al., 2018). Post-transcriptional modifications have also been observed, such as cytosine methylation by NSun7, which may promote stability of eRNAs (Agüilo et al., 2016). Another study found enrichment of N6-methyladenosine (m^6A) among enhancer-derived long intergenic non-coding RNAs (e-lncRNAs), which plays roles in RNA structure, stability, and processing (Xiao et al., 2019). Thus, the true diversity of eRNAs is not captured in its lengths or directionality of transcription, but in the various biological functions its secondary structures and post-transcriptional modifications portend.

An important issue for eRNA classification is the relationship between eRNA and IncRNAs. Long polyadenylated eRNAs are structurally similar to IncRNAs, but are transcribed from active enhancers rather than promoters. However, whereas much of our understanding of promoters comes from coding genes, many promoters do not fit the classic TATA structure. The rigidity of a binary promoter/enhancer paradigm blurs outside the context of coding genes, and it has been shown that some promoters may act as enhancers depending on the context (Mikhaylichenko et al., 2018; Rennie et al., 2018). Our emerging understanding may therefore unify long polyadenylated eRNAs and IncRNAs into a single class of regulatory RNAs transcribed from regulatory regions. Continuous re-evaluation of eRNA classification and grouping will be necessary as our understanding and definition of enhancer regions and non-coding RNAs continues to evolve.

Taken together, the above studies highlight that eRNAs are a heterogeneous and, as yet, poorly defined group of molecules. This diversity certainly leads to distinct biological functions, which will be discussed below, as we review the functional roles for eRNAs in gene regulation.

**BIOLOGICAL FUNCTIONS OF eRNA**

**eRNA as Regulators of Gene Expression**

A central issue regarding our current understanding of eRNA is whether the transcription of eRNA or the eRNA itself is primarily responsible for observed functions. For example, active transcription at enhancer sites can alter chromatin architecture and epigenetics and can recruit specific proteins to the enhancers (Kaikkonen et al., 2013; Meng et al., 2014; Benner et al., 2015). Additionally, antisense transcription of intragenic enhancers may play a role in attenuating and fine-tuning gene transcription by interfering with or pausing the sense mRNA transcription (Cinghu et al., 2017). Thus, transcription at enhancers may be correlated with significant biological phenomena without the produced eRNA playing a direct role in that phenomena.

Nevertheless, emerging evidence implicates a role for eRNA itself in transcription regulation. On a genomic scale, eRNA transcription and induction of mRNA transcription at neighboring genes are correlated (Kim et al., 2010; Kaikkonen et al., 2013; Li et al., 2013; Andersson et al., 2014a; Arner et al., 2015; Cheng et al., 2015; Dorighi et al., 2017; Ren et al., 2017; Imamura et al., 2018). RNAPII is not only abundantly present at active enhancers, but appears to be critical to their function as ubiquitination and dismissal of RNAPII leads to enhancer decommission and downregulation of target genes (Tan et al., 2018). eRNA knockdown studies have demonstrated important roles for individual eRNAs in the regulation of their target genes (Supplementary Table 1). Additional studies have shown that exogenous overexpression of eRNAs leads to an increase in their respective mRNA targets (Alvarez-Dominguez et al., 2017; Shi et al., 2017; Jiao et al., 2018). These studies have provided the
bulk of evidence implicating a directly causal role for eRNA, rather than the act of transcription, in the association between enhancer and mRNA transcription. However, it remains unclear how generalizable these instances are across the tens of thousands of enhancers known to transcribe eRNAs. Thus, the relevant question is not if eRNAs have a biological role, but which eRNAs are functional, and how eRNA function is linked to structure and localization.

Enhancer RNAs appear to be specific for their putative targets. This is based on the observation of strong correlation between eRNA transcription and neighboring mRNA transcription, as well as in knockdown experiments that show selective decrease in corresponding mRNAs when specific eRNAs are knocked down (Supplementary Table 1) (Arner et al., 2015). It is generally presumed that such specificity is largely context-dependent and driven by proximity and other factors controlling enhancer-promoter interactions (see van Arensbergen et al. (2014) for review of enhancer-promoter specificity). However, ectopically expressed Bloodlinc and SERPINB2 eRNAs have also shown the ability to selectively upregulate their respective mRNAs suggesting that, at least among these eRNAs, mere proximity is insufficient to explain their specificity for their targets (Alvarez-Dominguez et al., 2017; Shii et al., 2017). Several studies utilizing reporter assays to investigate how eRNAs promote transcription at their respective mRNA promoter have demonstrated the importance of the specific eRNA sequence in promoting transcription compared to truncated or “missense” RNA transcripts (Lam et al., 2013; Li et al., 2013; Melo et al., 2013). One such study observed that eRNA known to upregulate a different mRNA did not increase expression in their reporter, suggesting specificity of eRNA-promoter interactions (Aguilo et al., 2016). These studies suggest there are specific features (such as sequence or secondary structures) that confer eRNA function and that such traits may even provide for specific eRNA-promoter interactions. The traits and mechanisms for such intrinsic specificity remain elusive, but could include interactions with protein complexes, base-pairing with target DNA, or other undefined mechanisms.

Mechanisms of Action

In spite of the abundance of evidence supporting eRNAs as functional biomolecules, the exact mechanism by which they promote gene transcription remains enigmatic. However, several potential mechanisms of action are emerging including promotion of enhancer-promoter interactions, chromatin modifications, or regulation of transcriptional machinery (Figure 2). These potential mechanisms are not mutually exclusive and are effected through interactions with nuclear proteins. For example, DRR-eRNA and Bloodlinc eRNA were shown by mass spectrometry to bind to over 30 proteins, many of which have known functions in chromatin remodeling and gene regulation (Alvarez-Dominguez et al., 2017; Tsai et al., 2018). eRNA-protein interactions may play roles in protein recruitment, altering protein interactions, and providing scaffolding. An example is the cooperation of eRNA with YY1, a transcription factor with both DNA and RNA binding activity. RNAs tethered near enhancer loci were shown to increase the presence of YY1 specifically at those loci, perhaps due to “transcription factor trapping” wherein nascent RNA from enhancers and promoters increase the affinity of otherwise weak DNA-TF interactions creating a kinetic sink that would “trap” escaped transcription factors (Sigova et al., 2015). Such a model may explain observations that eRNA increases the binding of transcription factors such as c-Jun and NF-κB to target loci (Shii et al., 2017; Spurlock et al., 2017; Huang Z. et al., 2018). An emerging idea for how eRNAs may interact with large numbers of proteins is through phase separation. Phase separation describes the large-scale, three-dimensional concentration of proteins and nucleic acids (Box 1) and is a means by which transcriptional machinery and multiple regulatory elements are brought together. Phase separation of enhancers has been shown at super enhancers and at enhancers utilizing the MegaTrans complex (Sabari et al., 2018; Nair et al., 2019). While much remains to be learned, the literature overall supports a model wherein eRNAs contribute to enhancer function by interacting with nuclear proteins to promote enhancer-promoter looping, chromatin modification, and regulation of transcriptional machinery, possibly through phase separation.

Enhancer-Promoter Interaction

The traditional mode of action by active enhancers in regulating distant target genes is through chromatin looping to engage the gene promoters. Shortly after their discovery, it was noted that eRNAs were prominent at looped enhancers, but whether eRNA played a role in that looping process was less clear (Wang et al., 2011; Sanyal et al., 2012). It has been shown that eRNA transcription and chromatin looping occur concomitantly at the β-globin locus control region, which precedes gene transcription (Kim et al., 2015). The first study to propose enhancer-promoter interactions as a potential role for eRNA function was conducted by Li et al. (2013). Using chromosomal conformation capture analysis and siRNA knockdown to investigate changes in eRNA-enhancer-promoter interactions in response to estrogen stimulation, they observed that the knockdown of eRNAs resulted in decreased interactions between the enhancer and its nearest promoter. These studies found through in vitro transcribed (IVT) RNA-pulldown, RNA immunoprecipitation (RIP), and RIP-qPCR approaches, that eRNAs interacted with the RAD21 and SMC3 subunits of the cohesin complex. Knockdown of eRNAs by siRNA or locked nucleic acid (LNA) resulted in decreased recruitment of cohesin to those enhancers as determined by RAD21 ChIP, thus providing one of the early demonstrations of a functional role for eRNA. A later study found that RNA is able to stabilize some enhancer-promoter loops. RNase H1 digestion of RNA prevents RAD21 association with chromatin, thus implicating RNA-RAD21 interactions in formation and stabilization of promoter-enhancer loops (Pezone et al., 2019).

Similarly, the Evf2 eRNA is transcribed from an ultra-conserved enhancer (UCE) region that helps regulate enhancer interactions in trans and long-range cis (over 31 Mb) in vertebral interneurons. 4C-seq and ChIP-seq (cohesin subunits SMC1 and SMC3) analyses between Evf2+ and Evf2− knockout mouse ganglionic eminences demonstrated that Evf2 regulates cohesin
and localization of cohesin in undifferentiated muscle cells, interact with SMC3.

2018). Additionally, the 5' positioning to direct long-range UCE interactions (Cajigas et al., 2017).

Distinct regions of DRR eRNA were shown to interact with SMC3. DRR eRNA is necessary for the recruitment and localization of cohesin in undifferentiated muscle cells, and its depletion reduces chromatin accessibility and cell differentiation (Tsai et al., 2018).

Several subsequent studies have shown decreases in promoter-enhancer chromatin looping with knockdown of the respective eRNA (Pnueli et al., 2015; Liang et al., 2016; Yang et al., 2016; Tan et al., 2019). In addition to cohesin, heterogeneous nuclear ribonucleoprotein U (hnRNPU) and Mediator complex have also been implicated in eRNA mediated enhancer-promoter looping (Hsieh et al., 2014; Lai et al., 2015; Pnueli et al., 2015; Jiao et al., 2018; Tan et al., 2019). Expression of oncogenic heparanase (HPSE) is controlled by a super enhancer and its cognate eRNA
to impact various histone marks (Shii et al., 2017), but its most role for eRNAs in creating or maintaining open chromatin regions (as measured by DNase-seq or ATAC-seq), suggesting shown to decrease the accessibility of their respective enhancer associated proteins. Indeed, knockdown of eRNA has been important roles through their interactions with chromatin-modifying enzymes such as the cohesin and mediator complexes, but Clearly, eRNAs can interact with necessary DNA looping machineries such as the cohesin and mediator complexes, but how eRNA may interact with epigenetic modifiers such as PRC2 to promote or maintain looping during transition from poised to active enhancers merits further investigation.

In contrast, other studies have found that enhancer-promoter architecture was maintained in spite of eRNA knockdown or treatment with the RNAPII inhibitor flavopiridol to prevent eRNA transcription (Hah et al., 2013; Schaukowitch et al., 2014). In another study, a polyadenylation termination signal was inserted 80 bp downstream of the Lockd eRNA preventing production of the full eRNA. Notwithstanding, transcription of the target gene CDK91b and promoter-enhancer looping were not altered (Paralkar et al., 2016). There are several potential explanations for these conflicting studies. Some basal level eRNA transcription can occur and ongoing eRNA transcription may not be necessary during mRNA transcription (Rahman et al., 2017). Thus, it may be that enhancer-promoter interactions were established and maintained at these loci before eRNA knockdown. It may also be that eRNA at these loci are not essential for looping, play other roles, or are non-functional. Clearly, eRNAs can interact with necessary DNA looping machinery such as the cohesin and mediator complexes, but the circumstances and mechanisms through which they stabilize, recruit, or guide such complexes to their respective targets remains largely unknown.

Modifying Chromatin Accessibility

Most eRNAs are chromatin-associated, as opposed to free in the nucleoplasm or the cytoplasm (Cinghu et al., 2017; Shii et al., 2017). It may therefore be that eRNAs play important roles through their interactions with chromatin-associated proteins. Indeed, knockdown of eRNA has been shown to decrease the accessibility of their respective enhancer regions (as measured by DNase-seq or ATAC-seq), suggesting a role for eRNAs in creating or maintaining open chromatin (Mousavi et al., 2013; Tsai et al., 2018). eRNA has been shown to impact various histone marks (Shii et al., 2017), but its most prominent impact appears to be in modulating acetylation and methylation of H3K27.

The CBP and p300 histone acetyltransferases have been shown to interact with eRNAs (Bose et al., 2017; Jiao et al., 2018), and eRNA knockdown results in decreased H3K27ac at its respective enhancer and target-promoter regions (Pnueli et al., 2015; Liang et al., 2016; Bose et al., 2017; Shii et al., 2017). Bose et al. (2017) demonstrated that eRNAs interact with an RNA binding region within the activation loop of the CBP HAT domain. eRNA displaced the activation loop from the catalytic site and increased the affinity of CBP for its histone substrates. However, a subsequent report challenged these findings as they were unable to reproduce them when looking at p300 unless p300 was purified in buffer containing EDTA (Ortega et al., 2018). Further studies will therefore be needed to clarify if these results represent unique activation mechanisms for p300 and CBP vs. experimental artifact.

Enhancer RNA not only increases H3K27ac but also decreases transcriptionally repressive H3K27me3 levels (Pnueli et al., 2015). This may occur through interactions with the PRC2 complex, which represses transcription through addition of H3K27me3 (Cao et al., 2002). The EZH2 and SUZ12 subunits of PRC2 bind nascent RNA promiscuously with the EZH2 subunit binding to a guanine quadruplex motif in RNA (Kaneko et al., 2013; Wang et al., 2017). PRC2 binding of nascent RNA antagonizes its nucleosome binding activity and protects active gene transcription by inhibiting the methyltransferase activity of PRC2 (Cifuentes-Rojas et al., 2014; Beltran et al., 2016). The eRNA CARMEN has been shown to interact with EZH2 and SUZ12 to alter cardiac precursor cell development and differentiation through epigenetic regulation (Ounzain et al., 2015). These studies, in conjunction with the previously discussed studies showing the importance of H3K27ac and the H3K27me2/3 demethylase Kdm6a/b to eRNA production (Li et al., 2017; Kyzar et al., 2019), suggest that eRNAs promote a feed-forward loop of eRNA production and enhancer activation. eRNA production is stimulated by demethylases like Kdm6a/b (Li et al., 2017; Kyzar et al., 2019), and nascent eRNAs protect H3K27 from repressive methylation (Pnueli et al., 2015) and recruit and activate acetyltransferases to promote H3K27 hyperacetylation (Bose et al., 2017; Jiao et al., 2018). This leads to BRD4 recruitment and stabilization (Rahnamoun et al., 2018), additional eRNA production (Kanno et al., 2014), and enhancer activation.

Regulation of Transcriptional Machinery

In addition to promoter-enhancer looping and histone modifications, eRNAs interact with transcriptional machinery such as transcription factors, BRD4, and RNAPII. eRNA knockdown decreases binding of transcription factors at respective promoter and enhancer loci, perhaps due to loss of the “transcription factor trapping” mechanism previously discussed (Sigova et al., 2015; Spurlock et al., 2017; Huang et al., 2018). Additionally, the bromodomains of BRD4 have been shown to directly interact with eRNA. This interaction strengthens the affinity of BRD4 for acetylated histones, increases BRD4 and RNAPII recruitment, and promotes transcription
eRNAs can also recruit RNAPII to both enhancer and promoter loci independently of transcription factor binding to the enhancer (Lai et al., 2013; Mousavi et al., 2013; Maruyama et al., 2014; Yang et al., 2016). Once recruited, eRNA interacts with the NELF and P-TEFb complexes to regulate pause-release of RNAPII and promote enhancer and gene transcription (Schaukowitch et al., 2014; Shii et al., 2017). Kinetically, eRNA first interacts with the p-TEFb subunit CDK9, which phosphorylates NELF and serine 2 of the RNAPII CTD – a critical step for elongation (Shii et al., 2017). Next, eRNA is able to bind to the NELF-E subunit and outcompete nascent mRNA molecules that induce RNAPII stalling when binding NELF-E (Schaukowitch et al., 2014). This leads to eviction of NELF from chromatin and RNA elongation (Schaukowitch et al., 2014; Shii et al., 2017). This mechanism was demonstrated in vivo in rat amygdala as LNA knockdown of Arc eRNA lead to decreased Arc expression and increased NELF-E occupancy at the Arc promoter (Kyzar et al., 2019). The binding of eRNA to NELF-E is believed to be non-specific and mediated by promoter-enhancer looping bringing the eRNA into close proximity with the transcriptional machinery. One complex that may contribute to this is Integrator. Integrator has been shown to interact with NELF and DSIF pausing machinery at the proximal promoter and to impact transcription initiation and RNAPII pausing (Gardini et al., 2014; Skaar et al., 2015). In conjunction with its role in eRNA cleavage and maturation, Integrator is uniquely positioned to promote productive eRNA interactions with transcriptional machinery (Lai et al., 2015). Importantly, NELF eviction is the only demonstrated mechanism that directly implicates eRNAs in enhancer mechanism and the production of its respective mRNA.

Assembly of Super Enhancers
Super enhancers are a recently defined enhancer structure; they occupy a large genomic segment in which dense clusters of enhancers are brought into close 3D proximity and collaborate to act as a single regulatory unit that drives high levels of gene transcription (Hnisz et al., 2013; Whyte et al., 2013; Hah et al., 2015; Sabari et al., 2018). As compared to typical enhancers, super enhancers are marked by dramatically increased levels of transcription factor occupancy; high levels of H3K4me1 and H3K27ac density; increased DNase I hypersensitivity; RNAPII occupancy; and Mediator, p300/CBP, cohesin, and BRD4 cofactor occupancy (Box 2) (Hnisz et al., 2013; Whyte et al., 2013; Witte et al., 2015). Super enhancers are themselves transcribed and produce high quantities of eRNA relative to typical enhancers (Hah et al., 2015; Alvarez-Dominguez et al., 2017; Spurlock et al., 2017; Jiao et al., 2018; Tsai et al., 2018). shRNA knockdown of the eRNA from an Epstein-Barr Virus-induced super enhancer led to decreased H3K27ac, decreased looping between the super enhancer and the target MYC locus, and decreased MYC expression (Liang et al., 2016). Dysregulation of eRNA from super enhancers correlated with downregulation of respective striatal neuron identity genes in a mouse model of Huntington’s disease. This eRNA dysregulation was associated with decreased H3K27ac and a loss of RNAPII binding sites, suggesting the importance of these marks to both eRNA and super enhancer function (Le Gras et al., 2017). Similarly, a genome-wide association study found that differential eRNA expression in patients with autoimmune disease was especially localized to super enhancers near known genetic variants for autoimmune disease risk (Aune et al., 2017). Thus, eRNA appears to play an important role in super enhancer biology.

(Kanno et al., 2014; Rahnamoun et al., 2018). eRNAs can also recruit RNAPII to both enhancer and promoter loci independently of transcription factor binding to the enhancer (Lai et al., 2013; Mousavi et al., 2013; Maruyama et al., 2014; Yang et al., 2016). Once recruited, eRNA interacts with the NELF and P-TEFb complexes to regulate pause-release of RNAPII and promote enhancer and gene transcription (Schaukowitch et al., 2014; Shii et al., 2017). Kinetically, eRNA first interacts with the p-TEFb subunit CDK9, which phosphorylates NELF and serine 2 of the RNAPII CTD – a critical step for elongation (Shii et al., 2017). Next, eRNA is able to bind to the NELF-E subunit and outcompete nascent mRNA molecules that induce RNAPII stalling when binding NELF-E (Schaukowitch et al., 2014). This leads to eviction of NELF from chromatin and RNA elongation (Schaukowitch et al., 2014; Shii et al., 2017). This mechanism was demonstrated in vivo in rat amygdala as LNA knockdown of Arc eRNA lead to decreased Arc expression and increased NELF-E occupancy at the Arc promoter (Kyzar et al., 2019). The binding of eRNA to NELF-E is believed to be non-specific and mediated by promoter-enhancer looping bringing the eRNA into close proximity with the transcriptional machinery. One complex that may contribute to this is Integrator. Integrator has been shown to interact with NELF and DSIF pausing machinery at the proximal promoter and to impact transcription initiation and RNAPII pausing (Gardini et al., 2014; Skaar et al., 2015). In conjunction with its role in eRNA cleavage and maturation, Integrator is uniquely positioned to promote productive eRNA interactions with transcriptional machinery (Lai et al., 2015). Importantly, NELF eviction is the only demonstrated mechanism that directly implicates eRNAs in enhancer mechanism and the production of its respective mRNA.

Assembly of Super Enhancers
Super enhancers are a recently defined enhancer structure; they occupy a large genomic segment in which dense clusters of enhancers are brought into close 3D proximity and collaborate to act as a single regulatory unit that drives high levels of gene transcription (Hnisz et al., 2013; Whyte et al., 2013; Hah et al., 2015; Sabari et al., 2018). As compared to typical enhancers, super enhancers are marked by dramatically increased levels of transcription factor occupancy; high levels of H3K4me1 and H3K27ac density; increased DNase I hypersensitivity; RNAPII occupancy; and Mediator, p300/CBP, cohesin, and BRD4 cofactor occupancy (Box 2) (Hnisz et al., 2013; Whyte et al., 2013; Witte et al., 2015). Super enhancers are themselves transcribed and produce high quantities of eRNA relative to typical enhancers (Hah et al., 2015; Alvarez-Dominguez et al., 2017; Spurlock et al., 2017; Jiao et al., 2018; Tsai et al., 2018). shRNA knockdown of the eRNA from an Epstein-Barr Virus-induced super enhancer led to decreased H3K27ac, decreased looping between the super enhancer and the target MYC locus, and decreased MYC expression (Liang et al., 2016). Dysregulation of eRNA from super enhancers correlated with downregulation of respective striatal neuron identity genes in a mouse model of Huntington’s disease. This eRNA dysregulation was associated with decreased H3K27ac and a loss of RNAPII binding sites, suggesting the importance of these marks to both eRNA and super enhancer function (Le Gras et al., 2017). Similarly, a genome-wide association study found that differential eRNA expression in patients with autoimmune disease was especially localized to super enhancers near known genetic variants for autoimmune disease risk (Aune et al., 2017). Thus, eRNA appears to play an important role in super enhancer biology.
Defining super enhancers. Super enhancers are bioinformatically defined by having an exceptionally high concentration of enhancer markers such as cofactors, Mediator, and H3K27ac (Whyte et al., 2013). Traditionally, Med1, H3K27ac, and p300 have been used, although other factors such as BRD4 can be used and a similar profile is obtained (Whyte et al., 2013; Witte et al., 2015; Xiao et al., 2018). ChIP-seq data for H3K27ac (or other marker) is aligned to a reference genome and a peak calling algorithm defines regions of enrichment. Regions within close proximity of each other (12.5 kb as originally described) are stitched together and defined as a single region. All regions are then sorted and ranked according to signal strength (defined as rpm/bp). A graph is produced with the regions sorted by rank along the X-axis and signal strength in the Y-axis which produces an exponential curve (A). A line is drawn from the highest ranked enhancer to the lowest (B). That line is then slid along the curve until it is tangential to the curve (C). All regions ranked above this point are considered super enhancers, while those below are defined as typical enhancers (D).

Enhancers, eRNA, and Phase Separation
Recent studies have shown that super enhancers exist as liquid-liquid phase separated biomolecular condensates (Sabari et al., 2018) (Figure 3; see Box 1 for description of phase separation). Similarly, enhancers activated by the MegaTrans complex of transcription factors (MegaTrans enhancers) were shown to undergo phase separation (Liu et al., 2014; Nair et al., 2019). The activation domain of some transcription factors are also known to mediate phase separation (Boija et al., 2018). Recent evidence supporting the role of eRNA in phase separation and enhancer function was demonstrated with the MegaTrans complex. Using a combination of ChIP, fluorescently labeled IVT eRNAs, ASO, and FISH, Nair et al. (2019) showed that eRNAs from MegaTrans enhancers form enhancer ribonucleoprotein (eRNP) complexes with condensins. These eRNPs are necessary for phase separation and MegaTrans enhancer function. This is the first demonstration of eRNA playing a direct role in phase separation and enhancer function. eRNA may contribute to enhancer phase separation as a scaffolding member that is necessary for organizing phase separation and/or as a client member which participates in the structure and function (Banani et al., 2016). We will review evidences demonstrating how eRNA could impact phase separation as a scaffolding or client member. As phase separation may not be limited to defined “super enhancers” and may include other strongly activating enhancers, we will refer to all such enhancers as “phase separated enhancers” (PSE) in recognition that the following studies are applicable to but may not be limited to super enhancers.

RNA in general is known to act as a scaffold and directly contribute to the formation of many phase-separated structures. For example, competition for mRNA drives the formation and dissolution of P granules, while the lncRNA NEAT1 provides a scaffold for the formation of paraspeckles (Saha et al., 2016; Fox et al., 2018). Similarly, mRNA is able to phase separate cytosolic proteins when multiple m^6A methylations are present. The m^6A marks serve as binding platforms for YTHDF proteins and arranges their IDRs to induce phase separation (Ries et al., 2019). Interestingly, this same m^6A modification is enriched in eRNA (Xiao et al., 2019). eRNA is known to interact with proteins such as Med1 and BRD4, the IDRs of which contribute to super enhancer formation through phase separation (Sabari et al., 2018). Proteins in the MegaTrans complex are also enriched in IDRs (Nair et al., 2019). Thus, PSEs are enriched with proteins with IDRs and eRNA may serve as a scaffold for the induction of phase separation by interacting with RBDs in these proteins’ IDRs.

In addition to contributing to PSE formation, eRNA may also serve as a potential client and contribute to the composition, biophysical characteristics, and maturation of PSEs. For example, HPSE eRNAs interact with and recruit both hnRNPU and P300 to super enhancers (Jiao et al., 2018). Other hnRNPs, such as hnRNPA1, have been shown to undergo phase separation...
Arnold et al. eRNA Regulates Cell Fate Decisions

Super enhancer as phase-separated structure. Phase separated structures such as super enhancers are composed of scaffolding nucleic acids and proteins with intrinsically disordered regions (IDRs). Thermodynamically, they are favored to condense together at greater concentration than found in the cytoplasm, leading to formation of a membraneless phase separated structure. This allows the concentration of clientele proteins with similar biophysical properties and exclusion of other dissimilar proteins. By altering the stoichiometry of scaffolding or clients, cells can control the makeup of biomolecular condensates. In super enhancers, eRNA sequence motifs, secondary structures, or post-translational modifications such as m6A may be bound by Med1, BRD4, or other proteins with IDRs to promote organization, structure, and function of super enhancers.

Through IDRs, RBDs, and RNA (Lin et al., 2015; Molliex et al., 2015; Maharana et al., 2018; Wang et al., 2018), and the recruitment of hnRNPU or P300 to super enhancers by eRNA could model the ability of phase separated structures to fuse when in proximity. Intriguingly, the CTD of RNAPII is able to be recruited into biomolecular condensates (Cho et al., 2018). Its specific phosphorylation states affect its preferential incorporation into transcription initiation or splicing condensates (Guo et al., 2019). Such a model may also explain how RNAPII is recruited to super enhancers. This would explain the findings in studies showing eRNA playing a role in RNAPII recruitment to the MyoD super enhancer and other loci if eRNA were important to the phase separation (Mousavi et al., 2013; Maruyama et al., 2014). eRNA may also contribute to PSE maturation, as RNA is known to play important roles in maturation of many molecular condensates. The importance of condensate maturation to PSEs was demonstrated in MegaTrans enhancers where acutely activated enhancers were susceptible to chemical disruption of phase separation whereas chronically activated enhancers were resistant and assumed a more "gel-like" state (Nair et al., 2019). eRNA may therefore influence the composition of proteins recruited, the biophysical properties, and the stability or maturation of PSEs.

The high production of eRNA by PSEs, the pervasive interactions between eRNA and PSE components, and the critical role of RNAs in biomolecular condensate biology all suggest a critical relationship between eRNA and PSEs. These ideas were captured in the discovery of eRNPs as essential contributors to MegaTrans enhancers, and analogous complexes await discovery in super enhancers or other PSEs. Accordingly, outstanding questions regarding the formation, regulation, maintenance, dissolution, and longevity of super enhancers may find answers in eRNAs and their impacts on super enhancers as biomolecular condensates. Thus, the impact of eRNA on PSEs is a potentially significant biological role for eRNA. Future research will shed light on the role of eRNA as scaffold or client in PSEs and the impact such roles have on enhancer biology.

eRNAs AS MARKERS OF ACTIVE ENHANCERS

Because of their biological roles in gene transcription, eRNAs serve as markers of active enhancers. eRNA transcription per se is able to identify in vivo enhancers that are "caught in the act" of regulating mRNA/gene expression and does so independently of the local chromatin state or transcription factor binding (Kim et al., 2010; Wang et al., 2011; Sanyal et al., 2012; Hah et al., 2013; Andersson et al., 2014a; Wu et al., 2014; Arner et al., 2015; Cheng et al., 2015; Ren et al., 2017; Imamura et al., 2018). For example, one study found that eRNA served as a better marker of active enhancers than H3K27ac (Tyssowski et al., 2018). The ability to mark active enhancers in cells is an opportunity for unique insights, and several studies have begun to successfully utilize eRNA to mark active enhancer regions (Wang et al., 2011; Cauchy et al., 2016; Baillie et al., 2017;
eRNA expression profiles are highly tissue-specific (Koch et al., 2011; Djebali et al., 2012; Arner et al., 2015; Cheng et al., 2015; Ren et al., 2017) and can differentiate between different activation states of cells (Benner et al., 2015; Denisenko et al., 2017). As there are many more enhancer regions than gene loci, utilizing eRNA may provide unique opportunities and advantages for diagnosing, prognosticating, treating, and understanding the pathogenesis of diseases that aren’t afforded by current biomarkers. Multiple genome-wide association studies have found that most disease associated mutations occur outside the coding genome, and that a majority of those occur in enhancers or their transcribed RNAs (Farh et al., 2014; Aune et al., 2017). Accordingly, eRNAs are beginning to be utilized to map specific disease states and show the ability to identify disease-specific variants in a broad range of diseases including autoimmunity, cancer, infectious disease, cardiac hypertrophy, recurrent pregnancy loss, psychiatric, and neurological disorders (Farh et al., 2014; Witte et al., 2015; Liang et al., 2016; Aune et al., 2017; Le Gras et al., 2017; Ren et al., 2017; Hauber et al., 2018; Huang Z. et al., 2018; Isamura et al., 2018; Jiao et al., 2018; Gu et al., 2019; Kyzar et al., 2019; Mirtschink et al., 2019; Tan et al., 2019). The therapeutic potential of these studies was demonstrated when knockdown of the HERNA1 eRNA, which promotes pathological cardiac hypertrophy, protected mice from disease and reversed pathology in mice that had already developed the disease (Mirtschink et al., 2019). eRNA also provides a means for studying the dysregulation of mRNA in cancers and other diseases, as specific eRNAs have also been shown to hold prognostic value to patients with squamous cell carcinoma of the head and neck (Gu et al., 2019). We anticipate that the study of eRNA will continue to contribute to our understanding of the molecular pathogenesis and treatment of human disease.

**CONCLUSION AND FUTURE DIRECTIONS**

Enhancer RNAs are products of active enhancers and correlate with mRNA transcription of target genes but with unique expression profiles. Although broadly transcribed, eRNAs are a diverse array of RNAs with heterogeneous structure, length, and post-transcriptional modifications. Recent studies showing decreased gene transcription when eRNA is knocked down suggests that eRNAs have important roles in gene regulation and cellular biology. Mechanisms of action of eRNA include enhancer-promoter looping, chromatin modification, and regulation of transcriptional machinery. Importantly, the emergence of PSE such as super enhancers opens new possibilities for a role of eRNA as mediators of phase separation. The recent discovery that phase separation may be the means through which the activation domains of many transcription factors function, in addition to phase separation of MegaTrans enhancers, raises questions about the ubiquity of phase separation at enhancers and whether typical enhancers also utilize phase separation as a means to regulate gene expression. If so, eRNA-mediated phase separation may be the unified model by which various structures and forms of eRNA mediate looping, recruitment, and other biological functions. Future studies looking at eRNA should address whether the eRNA is transcribed from a phase-separated enhancer and if so, whether such eRNA is required for phase separation. Such studies promise to further elucidate the role of eRNA in the control of cell functions and fate decisions.

**AUTHOR CONTRIBUTIONS**

PA researched, developed, wrote the review, and created figures. AW and XL edited, developed, and provided direction to the review.

**FUNDING**

Funding for this review was provided through NIH R01AI129906.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2019.00377/full#supplementary-material

**REFERENCES**

Adam, R. C., Yang, H., Rockowiz, S., Larsen, S. B., Nikolova, M., Oristian, D. S., et al. (2015). Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. *Nature* 521, 366–370. doi: 10.1038/nature14289

Aguilo, F., Li, S., Balasubramaniyan, N., Sancho, A., Benko, S., Zhang, F., et al. (2016). Deposition of 5-methylcytosine on enhancer RNAs enables the coactivator function of PGC-1α. *Cell Rep.* 14, 479–492. doi: 10.1016/j.celrep.2015.12.043

Alvarez-Dominguez, J. R., Knoll, M., Gromatzky, A. A., and Lodish, H. F. (2017). The super-enhancer-derived alncRNA-EC7/bloodlinc potentiates red blood cell development in trans. *Cell Rep.* 19, 2503–2514. doi: 10.1016/j.celrep.2017.05.082

Andersson, R., Gebhard, C., Miguel-Escalada, I., Hoof, I., Bornholdt, J., Boyd, M., et al. (2014a). An atlas of active enhancers across human cell types and tissues. *Nature* 507, 455–461. doi: 10.1038/nature12787

Andersson, R., Refsing Andersen, P., Valen, E., Core, L. J., Bornholdt, J., Boyd, M., et al. (2014b). Nuclear stability and transcriptional directionality separate functionally distinct RNA species. *Nat. Commun.* 5:5336. doi: 10.1038/ncomms6336

Arner, E., Daub, C. O., Vitting-Seerup, K., Andersson, R., Lilje, B., Drablos, F., et al. (2015). Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. *Science* 347, 1010–1014. doi: 10.1126/science.1259448

Aune, T. M., Crooke, P. S. III, Patrick, A. E., Tossberg, J. T., Olsen, N. J., and Spurlock, C. F. III (2017). Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants. *J. Autoimmun.* 81, 99–109. doi: 10.1016/j.jaut.2017.03.014

Austenaa, L. M., Barozzi, I., Simonatto, M., Masella, S., Della Chiara, G., Ghisletti, S., et al. (2015). Transcription of mammalian cis-regulatory elements is restrained by actively enforced early termination. *Mol. Cell* 60, 460–474. doi: 10.1016/j.molcel.2015.09.018
Bailie, J. K., Arner, E., Daub, C., De Hoon, M., Itoh, M., Kawaji, H., et al. (2017). Analysis of the human monocyte-derived macrophage transcriptome and response to lipopolysaccharide provides new insights into genetic etiology of inflammatory bowel disease. PLoS Genet. 13, e1006641. doi: 10.1371/journal.pgen.1006641

Banani, S. F., Lee, H. O., Hyman, A. A., and Rosen, M. K. (2017). Biomolecular condensates: organizers of cellular biochemistry. Nat. Rev. Mol. Cell Biol. 18, 285–298. doi: 10.1038/nrm.2017.7

Banani, S. F., Rice, A. M., Peeples, W. B., Lin, Y., Jain, S., Parker, R., et al. (2016). Compositional control of phase-separated cellular bodies. Cell 166, 651–663. doi: 10.1016/j.cell.2016.06.010

Barbieri, E., Trizzino, M., Welsh, S. A., Owens, T. A., Calabretta, B., Carroll, M., et al. (2018). Targeted enhancer activation by a subunit of the integrator complex. Mol. Cell 71, 103.e7–116.e7. doi: 10.1016/j.molcel.2018.05.031

Beltran, M., Yates, C. M., Skalska, L., Dawson, M., Reis, F. P., Viiri, K., et al. (2016). The interaction of PRC2 with RNA or chromatin is mutually antagonistic. Genome Res. 26, 896–907. doi: 10.1101/gr.197632.115

Benner, C., Isoda, T., and Murre, C. (2015). New roles for DNA cytosine enhancers. Science 350, 574–578. doi: 10.1126/science.132415111

Bose, D. A., Donahue, G., Reinberg, D., Shiekhattar, R., Bonasio, R., and Brunelle, M., et al. (2018). Targeted enhancer activation by a subunit of the integrator complex. Mol. Cell 71, 103.e7–116.e7. doi: 10.1016/j.molcel.2018.05.031

Borrero, S., Fueyo, R., et al. (2014). Tyrosine phosphorylation of RNA polymerase II CTD is associated with antisense promoter transcription and active enhancers in mammalian cells. eLife 3: e02105. doi: 10.7554/eLife.02105

Björklund, J., Heidemann, M., Spinelli, L., Schüller, R., Maagool, M. A., Fenoul, R., et al. (2017). Genome-wide profiling of transcribed enhancers during macrophage activation. Epigenetics Chromatin 10:50. doi: 10.1186/s13072-017-0158-9

Bos, D. A., Donahue, G., Reinberg, D., Shiekhattar, R., Bonasio, R., and Brunelle, M., et al. (2018). Compositional control of phase-separated cellular bodies. Cell 166, 651–663. doi: 10.1016/j.cell.2016.06.010

Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., et al. (2012). Landscape of transcription in human cells. Nature 489, 101–108. doi: 10.1038/nature11233

Dorighi, K. M., Swigut, T., Henriques, T., Bhanu, N. V., Scruggs, B. S., Nady, N., et al. (2017). MI3 and MI4 facilitate enhancer RNA synthesis and transcription from promoters independently of H3K4 monomethylation. Mol. Cell 66, 568.e4–576.e4. doi: 10.1016/j.molcel.2017.04.018

Farh, K. K.-H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W. J., Beik, S., et al. (2014). Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337–343. doi: 10.1038/nature13835

Fox, A. H., Nakagawa, S., Hirose, T., and Bond, C. S. (2018). Paraspeckles: where long noncoding RNA meets phase separation. Trends Biochem. Sci. 43, 124–135. doi: 10.1016/j.tibsp.2017.12.001

Fukasawa, R., Iida, S., Tsutsui, T., Hirose, Y., and Ohkuma, Y. (2015). Mediator complex cooperatively regulates transcription of retinoic acid target genes with polycytome repressive complex 2 during neuronal differentiation. J. Biochem. 158, 373–384. doi: 10.1093/jb/mvz055

García-González, E., Escamilla-Del-Arenal, M., Arzate-Mejía, R., and Recillas-Targa, F. (2016). Chromatin remodeling effects on enhancer activity. Cell. Mol. Life Sci. 73, 2897–2910. doi: 10.1007/s00018-016-2184-3

Gardini, A., Bailatt, D., Cersosini, M., Hu, D., Marinis, J. M., Wagner, E. J., et al. (2014). Integrator regulates transcriptional initiation and pause release following activation. Mol. Cell 56, 128–139. doi: 10.1016/j.molcel.2014.08.004

Gosselin, D., Link, V. M., Romanoski, C. E., Fonseca, G. J., Eichenfield, D. Z., Spann, N. J., et al. (2014). Environment drives selection and function of enhancers controlling tissue-specific macrophase identities. Cell 159, 1327–1340. doi: 10.1016/j.cell.2014.11.023

Gu, X., Wang, L., Boldrup, L., Coates, P. J., Fahraeus, R., Sgaramella, N., et al. (2019). AP001056.1, a prognosis-related enhancer RNA in squamous cell carcinoma of the head and neck. Cancers 11:E347. doi: 10.3390/cancers11030347

Guo, Y. E., Manteiga, J. C., Henninger, J. E., Sabari, B. R., Dall’Agnese, A., Hannett, N. M., et al. (2019). Pol II phosphorylation regulates a switch between transcriptional and splicing condensates. Nature 572, 543–548. doi: 10.1038/s41586-019-1464-0

Hah, N., Benner, C., Chong, L. W., Yu, R. T., Downes, M., and Evans, R. M. (2015). Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs. Proc. Natl. Acad. Sci. U.S.A. 112, E297–E302. doi: 10.1073/pnas.142028112

Hah, N., Murakami, S., Nagari, A., Danko, C. G., and Kraus, W. L. (2013). Enhancer transcripts mark active estrogen receptor binding sites. Genome Res. 23, 1210–1223. doi: 10.1101/gr.152306.112

Hauberg, M. E., Fullard, J. F., Zhu, L., Cohain, A. T., Giambartolomei, C., Misir, R., et al. (2018). Differential activity of transcribed enhancers in the prefrontal cortex of 537 cases with schizophrenia and controls. Mol. Psychiatry 23, 1210–1223. doi: 10.1038/mp.2017.1340. doi: 10.1016/j.molcel.2014.11.023

Hafner, A., Brunelle, M., Nordell Markovits, A., Rodrigue, S., Lupien, M., Jacques, P. E., and Boisson, A. M., et al. (2012). Landscape of transcription in human cells. Nature 489, 101–108. doi: 10.1038/nature11233

Harr, K. K.-H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W. J., Beik, S., et al. (2014). Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337–343. doi: 10.1038/nature13835

Heslop, C. L., Fei, T., Chen, Y., Li, T., Gao, Y., Wang, X., et al. (2014). Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc. Natl. Acad. Sci. U.S.A. 111, 7319–7324. doi: 10.1073/pnas.1324151111
Huang, J., Li, K., Cai, W., Liu, X., Zhang, Y., Orkin, S. H., et al. (2018). Dissecting super-enhancer hierarchy based on chromatin interactions. Nat. Commun. 9:943. doi: 10.1038/s41467-018-03279-9

Huang, Z., Du, G., Huang, X., Han, L., Han, X., Xu, B., et al. (2018). The enhancer RNA Inc-SLC4A1-1 epigenetically regulates unexplained recurrent pregnancy loss (URPL) by activating CXCL8 and NF-kB pathway. EBioMedicine 38, 162–170. doi: 10.1016/j.ebiom.2018.11.015

Imamura, K., Takaya, A., Ishida, Y. I., Fukuoaka, Y., Taya, T., Nakaki, R., et al. (2018). Diminished nuclear RNA decay upon Salmonella infection upregulates antibacterial noncoding RNAs. EMBO J. 37:e977723. doi: 10.15252/embj.201797723

Jiao, W., Chen, Y., Song, H., Li, D., Mei, H., Yang, F., et al. (2018). HPSE enhancer RNA promotes cancer progression through driving chromatin looping and regulating hnRNP/3p00G/HPSE axis. Oncogene 37, 2728–2745. doi: 10.1038/s41388-018-0128-0

Kaikkonen, M. U., Spann, N. J., Heinz, S., Romanoski, C. E., Allison, K. A., Stender, J. D., et al. (2013). Remodeling of the enhancer landscape during macropHage activation is coupled to enhancer transcription. Mol. Cell 51, 310–325. doi: 10.1016/j.molcel.2013.07.010

Kanoke, S., Son, J., Shen, S. S., Reinberg, D., and Bonasio, R. (2013). PRC2 binds active promoters and contacts nascent RNAs in embryonic stem cells. Nat. Struct. Mol. Biol. 20:1258. doi: 10.1038/nsmb.2700

Kanno, T., Kanno, Y., LeRoy, G., Campos, E., Sun, H. W., Brooks, S. R., et al. (2014). BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat. Struct. Mol. Biol. 21, 1047–1057. doi: 10.1038/nsmb.2912

Kim, T.-K., Hemberg, M., Gray, J. M., Costa, A. M., Bear, D. M., Wu, J., et al. (2018). Integrator mediates the resolution. C1 CAGE detects transcription start sites and enhancer activity at single-cell resolution. Mol. Cell 51, 310–325. doi: 10.1016/j.molcel.2013.07.010

Kim, Y. W., Lee, S., Yun, J., and Kim, A. (2015). Chromatin looping and eRNA transcription precede the transcriptional activation of gene in the beta-globin locus. Biosci. Rep. 35:e00179. doi: 10.1042/bsr20140126

Koch, F., Fenouil, R., Gut, M., Cauchy, P., Albert, T. K., Zacarias-Cabeza, I., et al. (2011). Transcription initiation platforms and GTF recruitment at tissue-specific enhancers and promoters. Nat. Struct. Mol. Biol. 18, 956–963. doi: 10.1038/nsmb.2085

Kounou, T., Moody, J., Kwon, A. T., Shibayama, Y., Kato, S., Huang, Y., et al. (2019). C1 CAGE detects transcription start sites and enhancer activity at single-cell resolution. Mol. Commun. 15:360. doi: 10.1038/s41467-018-08126-5

Kyparissoudis, K., Papadopoulos, D. K., Richter, D., Pozniakovskaya, A., Poser, J., et al. (2018). RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science 360, 918–921. doi: 10.1126/science.aar7366

Kurokawa, K., Kurokawa, Y., Shibuya, S., Hasegawa, Y., and Kurokawa, Y. (2014). Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163, 123–133. doi: 10.1016/j.cell.2015.09.015

Li, X., Zhang, Q., Shi, Q., Liu, Y., Zhao, K., Shen, Q., et al. (2017). Demethylase Kdm6a epigenetically promotes IL-6 and IFN-beta production in macrophages. J. Autoimmun. 80, 85–94. doi: 10.1016/j.jaut.2017.02.007

Liang, J., Zhou, H., Gerdi, C., Tan, M., Colson, T., Kaye, K. M., et al. (2016). Epstein-Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation. Proc. Natl. Acad. Sci. U.S.A. 113, 14121–14126. doi: 10.1073/pnas.1616971113

Lin, Y., Pottier, D. S., Rosen, M. K., and Parker, R. (2015). Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. Mol. Cell 60, 208–219. doi: 10.1016/j.molcel.2015.08.018

Liu, Z., Merkurjev, D., Yang, F., Li, W., Oh, S., Friedman, M. J., et al. (2014). Enhancer activation requires trans-recruitment of a mega transcription factor complex. Cell 159, 358–373. doi: 10.1016/j.cell.2014.08.027

Maharaeda, S., Wang, J., Papadopoulos, D. K., Richter, D., Pozniakovskaya, A., Poser, J., et al. (2018). RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science 360, 918–921. doi: 10.1126/science.aar7366

Molin, A., Temirov, J., Lee, J., Coughlin, M., Kanagaraj, A. P., et al. (2015). Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163, 123–133. doi: 10.1016/j.cell.2015.09.015

Mousavi, K., Zare, H., Dell’orso, S., Grontved, L., Gutierrez-Cruz, G., Derouf, A., et al. (2013). eRNAs promote transcription by establishing chromatin accessibility at defined genomic loci. Mol. Cell 51, 606–617. doi: 10.1016/j.molcel.2013.07.022

Nair, S. J., Yang, L., Meluzzi, D., Oh, S., Yang, F., Friedman, M. J., et al. (2019). Phase separation of ligand-activated enhancers licenses cooperative chromosomal enhancer assembly. Nat. Struct. Mol. Biol. 26, 193–203. doi: 10.1038/s41594-019-0190-5

Nott, T. J., Petsalaki, E., Farber, P., Jervis, D., Fussner, E., Plowchowitz, A., et al. (2015). Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles. Mol. Cell 57, 936–947. doi: 10.1016/j.molcel.2015.01.013

Nunes, G., Estreicher, A., Bornhoitl, J., Chen, Y., Boyd, M., Jørgensen, M., et al. (2013). Polyadenylation site-induced decay of upstream transcripts enforces promoter directionality. Nat. Struct. Mol. Biol. 20, 923–928. doi: 10.1038/nsmb.2640

Ortega, E., Rengachari, S., Ibrahim, Z., Hoghoughi, N., Gaucher, J., Holehouse, A. S., et al. (2018). Transcription factor dimerization activates the p300 chromatin complex. Mol. Cell 62, 377–388. doi: 10.1016/j.molcel.2016.09.018
Pezone, A., Zuchegna, C., Tramontano, A., Romano, A., Russo, G., de Rosa, M., et al. (2019). RNA stabilizes transcription-dependent chromatin loops induced by nuclear hormones. Sci. Rep. 9:3925. doi: 10.1038/s41598-019-40213-6

Pruels, L., Rudniksz, S., Yosefzon, Y., and Melamed, P. (2015). RNA transcription from a distal enhancer is required for activating the chromatin at the promoter of the gonadotropin alpha-subunit gene. Proc. Natl. Acad. Sci. U.S.A. 112, 4369–4374. doi: 10.1073/pnas.1418411112

Pulakanti, K., Pinello, L., Stelloh, C., Blinka, S., Allred, J., Milanovich, S., et al. (2013). Enhancer transcribed RNAs arise from hypomethylated, Tet-occupied genomic regions. Epigenetics 8, 1303–1320. doi: 10.4161/epi.26597

Rahman, S., Zorca, C. E., Traboulsi, T., Noutahi, E., Krause, M. R., Mader, S., et al. (2017). Single-cell profiling reveals that eRNA accumulation at enhancer-promoter loops is not required to sustain transcription. Nucleic Acids Res. 45, 3017–3030. doi: 10.1093/nar/gkw1220

Rahmoun, H., Lee, J., Sun, Z., Lu, H., Ramsey, K. M., Komives, E. A., et al. (2019). RNA regulates transcriptional memory T cells. Cell. Immunol. 199, 547–558. doi: 10.1049/jimunol:1700232

Stadler, M. B., Murr, R., Burger, L., Ivanek, R., Lienert, F., Schölter, A., et al. (2011). DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 480, 490–495. doi: 10.1038/nature10716

Tan, S. H., Leong, W. Z., Ngoc, P. C. T., Tan, T. K., Bertuloo, F. C., Lim, M. C., et al. (2019). The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia. Blood 134, 239–251. doi: 10.1182/blood.2018874503

Tan, Y., Jin, C., Ma, W., Hu, Y., Tanasa, B., Oh, S., et al. (2018). Dismissal of RNA Polymerase II underlies a large ligand-induced enhancer decommissioning program. Mol. Cell 71, 526.e8–539.e8. doi: 10.1016/j.molcel.2018.07.039

Tsai, P. F., Dell’Orso, S., Rodriguez, J., Vivanco, K. O., Ko, K. D., Jiang, K., et al. (2018). A muscle-specific enhancer RNA mediates cohesin recruitment and regulates transcription in trans. Mol. Cell 71, 129.e8–141.e8. doi: 10.1016/j.molcel.2018.06.008

Tyossy, K. M., DeStefino, N. R., Cho, J.-H., Dunn, C. J., Poston, R. G., Carty, C. E., et al. (2018). Different neuronal activity patterns induce different gene expression programs. Neuron 98, 530.e11–546.e11. doi: 10.1016/j.neuron.2018.04.001

van Aremsergen, J., van Steensel, B., and Bussemaker, H. J. (2014). In search of the determinants of enhancer-promoter interaction specificity. Trends Cell Biol. 24, 695–702. doi: 10.1016/t.cbio.2014.07.004

Wang, D., Garcia-Bassets, I., Benner, C., Li, W., Xu, Z., Zhou, Y., et al. (2011). Reprogramming transcription by distinct classes of enhancers functionally defined by RNA. Nature 474, 390–394. doi: 10.1038/nature10006

Wang, J., Choi, J.-M., Holehouse, A. S., Lee, H. O., Zhang, X., Jahnel, M., et al. (2018). A molecular grammar governing the driving forces for phase separation of prion-like RNA binding proteins. Cell 174, 688.e16–699.e16. doi: 10.1016/j.cell.2018.06.006

Wang, X., Goodrich, K. J., Gooding, A. R., Naeem, H., Archer, S., Paeckel, R. D., et al. (2017). Targeting of polycomb repressive complex 2 to RNA by short repeats of consecutive guanines. Mol. Cell 65, 1056.e5–1067.e5. doi: 10.1016/j.molcel.2017.02.003

Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., et al. (2013). Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319. doi: 10.1016/j.cell.2013.03.035

Witte, S., Bradley, A., Enright, A. J., and Muljo, S. A. (2015). High-density P300 super-enhancers control cell state transitions. BMC Genomics 16:903. doi: 10.1186/s12864-015-1905-6

Wu, H., Nord, A. S., Akiyama, J. A., Shoukry, M., Afzal, V., Rubin, E. M., et al. (2014). Tissue-specific RNA expression marks distant-acting developmental enhancers. PLoS Genet. 10:e1004610. doi: 10.1371/journal.pgen.1004610

Xiao, S., Cao, S., Huang, Q., Xia, L., Deng, M., Yang, M., et al. (2019). The RNA N(6)-methyladenosine modification landscape of human fetal tissues. Nat. Cell Biol. 21, 651–661. doi: 10.1038/s41556-019-0315-4

Xiao, X., Fan, Y., Li, J., Zhang, X., Lou, X., Dou, Y., et al. (2018). Guidance of super-enhancers in regulation of IL-9 induction and airway inflammation. J. Exp. Med. 215, 559–574. doi: 10.1084/jem.20170928

Xiong, L., Wu, F., Wu, Q., Xu, L., Cheung, O. K., Kang, W., et al. (2019). Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. Nat. Commun. 10:335. doi: 10.1038/s41467-018-08245-z

Yang, Y., Su, Z., Song, X., Liang, B., Zeng, F., Chang, X., et al. (2016). Enhancer RNA-driven looping enhances the transcription of the long noncoding RNA DHRS4-AS1, a controller of the DHRS4 gene cluster. Sci. Rep. 6:20961. doi: 10.1038/srep20961

Zhang, H., Elbaum-Garfinkle, S., Langdon, E. M., Taylor, N., Occhipinti, P., Bridges, A. A., et al. (2015). RNA controls PolyQ protein phase transitions. Mol. Cell 60, 220–230. doi: 10.1016/j.molcel.2015.09.017

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Arnold, Wells and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.